Comparative Pharmacology
Head-to-head clinical analysis: PARAFLEX versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFLEX versus RYANODEX.
PARAFLEX vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant